Lepu Pharmaceutical Technology Co., Ltd.
-
Founded in:
2012-12-04 -
Country:
China -
Address:
No. 36, Weier Road, Xiangcheng Industrial Cluster Zone -
Tax NO.:
914116810587783761 -
Registered Funds:
50 million yuan -
Email:
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Losartan potassium |
Angiotensin II receptor (AT1 receptor) antagonists block all physiological effects related to angiotensin II, lower blood pressure, reduce aldosterone secretion and vasoconstriction, and do not affect bradykinin response.
More
Angiotensin II receptor (AT1 receptor) antagonists block all physiological effects related to angiotensin II, lower blood pressure, reduce aldosterone secretion and vasoconstriction, and do not affect bradykinin response. |
50mg | 124750-99-8 | 65 |
| Hydrochlorothiazide |
Diuretics increase the excretion of sodium and chloride, with a certain loss of potassium and bicarbonate, and have diuretic and antihypertensive effects.
More
Diuretics increase the excretion of sodium and chloride, with a certain loss of potassium and bicarbonate, and have diuretic and antihypertensive effects. |
12.5mg | 58-93-5 | 54 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Naproxen |
This product is a non-steroidal anti-inflammatory drug. Its analgesic, anti-inflammatory and antipyretic effects work by inhibiting the synthesis of prostaglandins.
More
This product is a non-steroidal anti-inflammatory drug. Its analgesic, anti-inflammatory and antipyretic effects work by inhibiting the synthesis of prostaglandins. |
22204-53-1 | 30 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Roxithromycin |
A new generation of macrolide antibiotics, it mainly acts on Gram-positive bacteria, anaerobic bacteria, Chlamydia and Mycoplasma, etc. Its in vitro antibacterial effect is similar to that of erythromycin, and its in vivo antibacterial effect is 1 to 4 times stronger than that of erythromycin.
More
A new generation of macrolide antibiotics, it mainly acts on Gram-positive bacteria, anaerobic bacteria, Chlamydia and Mycoplasma, etc. Its in vitro antibacterial effect is similar to that of erythromycin, and its in vivo antibacterial effect is 1 to 4 times stronger than that of erythromycin. |
80214-83-1 | 28 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Roxithromycin |
A new generation of macrolide antibiotics, it mainly acts on Gram-positive bacteria, anaerobic bacteria, Chlamydia and Mycoplasma, etc. Its in vitro antibacterial effect is similar to that of erythromycin, and its in vivo antibacterial effect is 1 to 4 times stronger than that of erythromycin.
More
A new generation of macrolide antibiotics, it mainly acts on Gram-positive bacteria, anaerobic bacteria, Chlamydia and Mycoplasma, etc. Its in vitro antibacterial effect is similar to that of erythromycin, and its in vivo antibacterial effect is 1 to 4 times stronger than that of erythromycin. |
80214-83-1 | 28 |